Free Technical Research on Insmed and Three More Biotech Equities

Stock Research Monitor: INFI, INVA, and INO

LONDON, UK / ACCESSWIRE / July 13, 2018 / If you want a free Stock Review on INSM sign up now at www.wallstequities.com/registration. On Thursday, July 12, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Innoviva Inc. (NASDAQ: INVA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Insmed Inc. (NASDAQ: INSM). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Infinity Pharmaceuticals

On Thursday, shares in Cambridge, Massachusetts headquartered Infinity Pharmaceuticals Inc. recorded a trading volume of 244,389 shares. The stock ended at $2.02, rising 1.00% from the last trading session. The Company's shares have gained 15.43% in the last month and 43.26% in the last twelve months. The stock is trading above its 50-day moving average by 2.53%. Furthermore, shares of Infinity Pharma, which develops medicines for people with cancer in the US, have a Relative Strength Index (RSI) of 56.29. Get the full research report on INFI for free by clicking below at: www.wallstequities.com/registration/?symbol=INFI.

Innoviva

Brisbane, California headquartered Innoviva Inc.'s stock finished yesterday's session 1.64% higher at $14.84. A total volume of 463,324 shares was traded. The Company's shares have gained 15.04% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 2.70% and 1.94%, respectively. Furthermore, shares of Innoviva, which engages in the development and commercialization of bio-pharmaceuticals, have an RSI of 59.47. Get access to our top-rated research, including the free report on INVA at: www.wallstequities.com/registration/?.symbol=INVA.

Inovio Pharmaceuticals

At the close of trading on Thursday, shares in Plymouth Meeting, Pennsylvania headquartered Inovio Pharmaceuticals Inc. ended the day flat at $4.47. The stock recorded a trading volume of 633,573 shares. The stock is trading below its 50-day moving average by 0.90%. Moreover, shares of Inovio Pharma, which develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases, have an RSI of 55.74. Click here to subscribe for a free membership which welcomes you with our report on INO at: www.wallstequities.com/registration/?symbol=INO.

Insmed

Bridgewater, New Jersey headquartered Insmed Inc.'s shares ended the day 1.29% lower at $25.86 with a total trading volume of 438,813 shares. The stock has gained 52.84% over the last twelve months. The Company's shares are trading below their 50-day moving average by 3.37%. Additionally, shares of Insmed, which focuses on the development and commercialization of therapies for patients with rare diseases, have an RSI of 49.06. To get free access to your research report on INSM, sign up at: www.wallstequities.com/registration/?symbol=INSM.

Wall St.Equities:

Wall St. Equities (WSE) producesregular sponsored and non-sponsored reports, articles, stock market blogs, andpopular investment newsletters covering equities listed on NYSE and NASDAQ andmicro-cap stocks. WSE has two distinct and independent departments. Onedepartment produces non-sponsored analyst certified content generally in theform of press releases, articles and reports covering equities listed on NYSEand NASDAQ and the other produces sponsored content (in most cases not reviewedby a registered analyst), which typically consists of compensated investmentnewsletters, articles and reports covering listed stocks and micro-caps. Suchsponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directlyor indirectly; for producing or publishing this document.

PRESS RELEASEPROCEDURES:

The non-sponsored content containedherein has been prepared by a writer (the "Author") and is factchecked and reviewed by a third-party research service company (the"Reviewer") represented by a credentialed financial analyst [forfurther information on analyst credentials, please email info@wallstequities.com.Rohit Tuli, a CFA® charterholder (the "Sponsor"), providesnecessary guidance in preparing the document templates. The Reviewer hasreviewed and revised the content, as necessary, based on publicly availableinformation which is believed to be reliable. Content is researched, writtenand reviewed on a reasonable-effort basis. The Reviewer has not performed anyindependent investigations or forensic audits to validate the informationherein. The Reviewer has only independently reviewed the information providedby the Author according to the procedures outlined by WSE. WSE is not entitledto veto or interfere in the application of such procedures by the third-partyresearch service company to the articles, documents or reports, as the case maybe. Unless otherwise noted, any content outside of this document has noassociation with the Author or the Reviewer in any way.

NOWARRANTY

WSE, the Author, and the Reviewer arenot responsible for any error which may be occasioned at the time of printingof this document or any error, mistake or shortcoming. No liability is acceptedwhatsoever for any direct, indirect or consequential loss arising from the useof this document. WSE, the Author, and the Reviewer expressly disclaim anyfiduciary responsibility or liability for any consequences, financial orotherwise arising from any reliance placed on the information in this document.Additionally, WSE, the Author, and the Reviewer do not (1) guarantee theaccuracy, timeliness, completeness or correct sequencing of the information, or(2) warrant any results from use of the information. The included informationis subject to change without notice.

NOT ANOFFERING

This document is not intended as anoffering, recommendation, or a solicitation of an offer to buy or sell thesecurities mentioned or discussed, and is to be used for informational purposesonly. Please read all associated disclosures and disclaimers in full beforeinvesting. Neither WSE nor any party affiliated with us is a registeredinvestment adviser or broker-dealer with any agency or in any jurisdictionwhatsoever. To download our report(s), read our disclosures, or for moreinformation, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, orcomments reach out to us directly. If you're a company,we are covering and wish to no longer feature on our coverage list contact usvia email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Fridayat:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, ShawCenter Singapore 228

CFA® and Chartered FinancialAnalyst® are registered trademarks owned by CFA Institute.

SOURCE:Wall St. Equities